LeMaitre Vascular’s (LMAT) “Outperform” Rating Reiterated at Barrington Research

Barrington Research reaffirmed their outperform rating on shares of LeMaitre Vascular (NASDAQ:LMAT) in a research report released on Friday, Benzinga reports. The brokerage currently has a $92.00 price target on the medical instruments supplier’s stock.

A number of other equities analysts have also commented on LMAT. Roth Mkm reaffirmed a buy rating and set a $100.00 price target on shares of LeMaitre Vascular in a research report on Friday, May 31st. Lake Street Capital assumed coverage on shares of LeMaitre Vascular in a research report on Friday, August 2nd. They set a buy rating and a $105.00 target price on the stock. StockNews.com downgraded shares of LeMaitre Vascular from a buy rating to a hold rating in a research report on Tuesday, August 27th. Roth Capital upgraded shares of LeMaitre Vascular to a strong-buy rating in a research report on Friday, May 31st. Finally, JMP Securities lifted their price objective on shares of LeMaitre Vascular from $77.00 to $100.00 and gave the company a market outperform rating in a research note on Tuesday, August 20th. Two equities research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, LeMaitre Vascular presently has an average rating of Moderate Buy and an average target price of $94.40.

LeMaitre Vascular Trading Down 0.2 %

Shares of LMAT opened at $89.96 on Friday. LeMaitre Vascular has a 12 month low of $44.27 and a 12 month high of $92.90. The firm has a fifty day simple moving average of $86.84 and a 200 day simple moving average of $78.14. The stock has a market capitalization of $2.02 billion, a price-to-earnings ratio of 59.58, a PEG ratio of 2.28 and a beta of 0.88.

LeMaitre Vascular (NASDAQ:LMAT) last announced its quarterly earnings results on Thursday, August 1st. The medical instruments supplier reported $0.52 EPS for the quarter, beating analysts’ consensus estimates of $0.47 by $0.05. The firm had revenue of $55.85 million during the quarter, compared to analysts’ expectations of $54.98 million. LeMaitre Vascular had a net margin of 18.33% and a return on equity of 12.41%. The company’s revenue for the quarter was up 11.4% compared to the same quarter last year. During the same quarter last year, the company posted $0.37 earnings per share. As a group, research analysts predict that LeMaitre Vascular will post 1.85 earnings per share for the current fiscal year.

LeMaitre Vascular Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Thursday, August 29th. Stockholders of record on Thursday, August 15th were paid a $0.16 dividend. The ex-dividend date of this dividend was Thursday, August 15th. This represents a $0.64 annualized dividend and a dividend yield of 0.71%. LeMaitre Vascular’s payout ratio is 42.38%.

Insider Buying and Selling

In other LeMaitre Vascular news, CEO George W. Lemaitre sold 12,976 shares of the company’s stock in a transaction dated Friday, July 12th. The shares were sold at an average price of $86.07, for a total transaction of $1,116,844.32. Following the sale, the chief executive officer now directly owns 1,985,358 shares of the company’s stock, valued at $170,879,763.06. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. In other news, CEO George W. Lemaitre sold 27,030 shares of the stock in a transaction dated Monday, July 15th. The shares were sold at an average price of $86.27, for a total value of $2,331,878.10. Following the sale, the chief executive officer now directly owns 1,958,328 shares of the company’s stock, valued at $168,944,956.56. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, CEO George W. Lemaitre sold 12,976 shares of the company’s stock in a transaction that occurred on Friday, July 12th. The stock was sold at an average price of $86.07, for a total transaction of $1,116,844.32. Following the completion of the transaction, the chief executive officer now owns 1,985,358 shares in the company, valued at $170,879,763.06. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 43,251 shares of company stock valued at $3,714,994. 10.79% of the stock is owned by insiders.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the stock. YHB Investment Advisors Inc. purchased a new stake in shares of LeMaitre Vascular during the first quarter valued at approximately $36,000. GAMMA Investing LLC increased its position in shares of LeMaitre Vascular by 57.0% during the 2nd quarter. GAMMA Investing LLC now owns 548 shares of the medical instruments supplier’s stock valued at $45,000 after purchasing an additional 199 shares during the last quarter. West Oak Capital LLC purchased a new stake in shares of LeMaitre Vascular during the 2nd quarter valued at about $58,000. nVerses Capital LLC grew its stake in shares of LeMaitre Vascular by 33.3% during the 2nd quarter. nVerses Capital LLC now owns 800 shares of the medical instruments supplier’s stock valued at $66,000 after acquiring an additional 200 shares during the period. Finally, Van ECK Associates Corp bought a new position in shares of LeMaitre Vascular during the 2nd quarter valued at approximately $75,000. 84.64% of the stock is currently owned by institutional investors.

About LeMaitre Vascular

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.